Novo Nordisk A/S Release: Clinical Study Shows Liraglutide Provides Statistically Significantly Better Blood Glucose Control than Exenatide

BAGSVÆRD, DENMARK--(Marketwire - June 06, 2008) - Novo Nordisk today announced headline clinical results from a phase 3 clinical study (LEAD™ 6) comparing the effects of liraglutide, a once-daily human GLP-1 analogue, with exenatide, a twice-daily GLP-1 analogue. The 26-week study, which is the first study to provide a direct comparison between the two GLP-1 analogues, included 464 people with type 2 diabetes who were randomised to treatment with either liraglutide once daily or exenatide twice daily, as add-on to their existing treatment consisting of metformin, sulfonylurea, or a combination of both.